Tezacaftor
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Tezacaftor: From Cystic Fibrosis to HIV Infectious Disease
One-Sentence Summary
Tezacaftor is a CFTR corrector, originally used in combination therapies for cystic fibrosis. The TxGNN model predicts it may be effective for HIV infectious disease, but this is a model prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cystic fibrosis |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 0.9924 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 7 of 7) |
| Number of DINs | 7 (marketed: 7) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, tezacaftor is a CFTR corrector that helps the F508del-CFTR protein fold and traffic to the cell surface. It is marketed in combination with ivacaftor (Symdeko) and in triple combinations (Trikafta, Alyftrek) for cystic fibrosis patients with specific gene mutations.
No established mechanistic link between CFTR correction and HIV pathogenesis is supported by the available data. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, so the prediction should be treated as speculative.
Other high-scoring predictions for this drug include leprosy and multiple endocrine neoplasia. Neither has clinical trial or literature support in the data compiled.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02478080 | SYMDEKO | Not specified | Not specified |
| 02542285 | TRIKAFTA | Not specified | Not specified |
| 02559676 | ALYFTREK | Not specified | Not specified |
| 02517140 | TRIKAFTA | Not specified | Not specified |
| 02526670 | TRIKAFTA | Not specified | Not specified |
Seven valid authorizations in total are listed, all for tezacaftor-containing products. The five above are the first five.
Safety Considerations
Please refer to the package insert for safety information.
The only interaction data compiled is a pharmacological target record: tezacaftor acts on the CFTR protein. No drug-drug interaction entries with other medicines are available.
Conclusion and Next Steps
Decision: Hold
Rationale: The HIV prediction is based on a model score alone (L5), with no registered clinical trials, no literature, and no plausible mechanistic link to CFTR correction in the available data. A high score by itself is not enough to justify moving forward.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank) to support or refute a link to HIV biology
- Health Canada package insert warnings and contraindications, which are required before any safety screening
- Preclinical evidence, such as in vitro antiviral activity of tezacaftor against HIV
- A review of whether the HIV, SIV and feline immunodeficiency predictions are one correlated signal
- Approved indication text and dosage forms for the Canadian licenses, which are currently missing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.